Study: J&J and Bayer's anticoagulant Xarelto yields mixed results

04/5/2011 | Reuters

A clinical study found that Bayer and Johnson & Johnson's anticoagulant Xarelto worked as well as standard injectable drug Lovenox, by Sanofi-Aventis, in preventing blood clots after 10 days of treatment among patients hospitalized for acute illnesses. However, the incidence of bleeding among Xarelto users after 35 days of treatment was more than double the rate seen in Lovenox users.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX